CAH vs COR
Cardinal Health and Cencora, both Healthcare
Cencora is the larger company at $62B against $55B. Over the past year CAH returned +60% against +13% for COR. The RyuScore puts COR ahead, 64 against 61 out of 100.
| Figure | CAH | COR |
|---|---|---|
| Last close | $238 | $325 |
| Market cap | $55B | $62B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 24.1 |
| Dividend yield | 0.9% | 0.7% |
| 1-year return | +60% | +13% |
| 5-year return | +408% | +183% |
| RyuScoresector-relative, 1–10 | 61/100 | 64/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cardinal Health
Revenue of $125B in H2 2026, net income $797M. Its largest reported line is Pharmaceutical And Specialty Solutions, 94% of the disclosed total.
Cencora
Revenue of $85B in Q3 2026, net income $764M. Its largest reported line is US Healthcare Solutions, 92% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.